Spero Therapeutics (SPRO) catalysts

Upcoming FDA decisions and readouts we track for Spero Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList has 1 catalyst on record for Spero Therapeutics (SPRO, listed on Nasdaq), all now decided. It concerns Utebzi (tebipenem pivoxil) (Complicated urinary tract infections including pyelonephritis).

Decided and on record:

Utebzi (tebipenem pivoxil), PDUFA date: Approved 17 June 2026, one day ahead of the PDUFA date.

Each outcome links to the filing or notice that reported it in the table below.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: SPRO
Next catalyst: —
Type: —
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Spero Therapeutics SPRO · Nasdaq	Utebzi (tebipenem pivoxil)	Complicated urinary tract infections including pyelonephritis	18 Jun 2026 111d ago	PDUFA date	Verified	8-K ↗	Yes
Notes — Filing states approval "was received in advance of FDA-assigned Prescription Drug User Fee Act (PDUFA) date of June 18, 2026." Outcome — Approved 17 June 2026, one day ahead of the PDUFA date Source: 8-K, filed 22 Jun 2026 · verified 11 Sep 2026

Companies working on related conditions

Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)